GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alk-Abello AS (OCSE:ALK B) » Definitions » Short Interest

Alk-Abello AS (OCSE:ALK B) Short Interest


View and export this data going back to 2005. Start your Free Trial

What is Alk-Abello AS Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Alk-Abello AS's Short Interest

For the Biotechnology subindustry, Alk-Abello AS's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alk-Abello AS's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alk-Abello AS's Short Interest distribution charts can be found below:

* The bar in red indicates where Alk-Abello AS's Short Interest falls into.


;
;

Alk-Abello AS Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alk-Abello AS (OCSE:ALK B) » Definitions » Short Interest
Comparable Companies
OCSE:ZEAL OCSE:BAVA OCSE:GUBRA OCSE:GMAB OCSE:PEG OCSE:STRAP VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:UCB XBRU:ARGX ONC XKRX:068270 BNTX INSM HKSE:01801 SMMT RPRX
Traded in Other Exchanges
ALKBc:UK 0OIR:UK 4AJ0:Germany
Address
Boge Alle 6-8, Horsholm, DNK, DK-2970
Website
https://www.alk.net
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.

Alk-Abello AS Headlines

No Headlines